Clinical trialNCT06531499RecruitingPhase 1Interventional

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

SponsorNovartis PharmaceuticalsEnrollment106Metastatic Castration-Resistant Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Germany

Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Recruiting
Novartis Investigative Site
Wuppertal, North Rhine-Westphalia, Germany
Recruiting
Novartis Investigative Site
Aachen, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Essen, Germany
Recruiting
Novartis Investigative Site
München, Germany
Recruiting
Novartis Investigative Site
Rostock, Germany
Recruiting

Netherlands

Novartis Investigative Site
Nijmegen, Gelderland, Netherlands
Recruiting

Spain

Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Recruiting
Novartis Investigative Site
Majadahonda, Madrid, Spain
Recruiting
Novartis Investigative Site
Barcelona, Spain
Recruiting

Switzerland

Novartis Investigative Site
Bellinzona, Switzerland
Recruiting
Novartis Investigative Site
Bern, Switzerland
Recruiting

United Kingdom

Novartis Investigative Site
Sutton, Surrey, United Kingdom
Recruiting
Novartis Investigative Site
Birmingham, West Midlands, United Kingdom
Recruiting
Novartis Investigative Site
Glasgow, United Kingdom
Recruiting

United States

University of California la
Los Angeles, California, United States
Matthew Rettig
Recruiting
Stanford University
Palo Alto, California, United States
Hong Song
Recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Daniel Childs
Recruiting
Wash U School of Medicine
St Louis, Missouri, United States
Vikas Prasad
Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Samuel Mehr
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Nov 2024
Primary completion: 24 Nov 2028
Completion: 24 Nov 2028
Last update posted: 31 Dec 2025
Registered enrollment: 106
Registry id: NCT06531499

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-512338-13

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.